SAT0039 Large tender joints have the greatest impact on longitudinal trajectories of function in early rheumatoid arthritis
2017
Background Physical function remains suboptimal in patients with early rheumatoid arthritis (ERA) despite adequate disease control. Hence, factors impacting function need further evaluation. Large weight bearing joints are more likely to impact overall function than small non-weight bearing joints although the magnitude of impact may be task dependent. By weighting large joints more than small joints, the Lansbury Articular Index (LAI) may have stronger associations with function than standard joint counts that give equal weight to small and large joints. Objectives 1) To compare the correlations of weighted and non-weighted arthritis joint measures with physical function over time; and 2) to determine the impact of large compared to small joint involvement on the trajectory of HAQ in ERA. Methods ERA participants had Results ERA subjects (n=2125, 73% female; baseline mean (SD) age 53 (15) years, DAS28 5.1 (1.4)), were followed for median (IQR) 24 (10,48) months. At their last visit 44% were in remission (DAS28 Conclusions Both Lansbury and standard joint count trajectories correlate similarily with HAQ in ERA. The weighting of large joints in LAI was insufficient to reflect the full impact of large joint involvement in ERA probably because HAQ questions emphasize large joint activities. The effects of large joint swelling may be under recognized due to difficulty in measuring hip, shoulder or elbow swelling. Overall, tender joints had a greater impact on function than swollen joints and large tender joints had the most impact on function. Disclosure of Interest S. H. L. Lim: None declared, O. Schieir: None declared, S. Bartlett Consultant for: Pfizer UCB, G. Boire: None declared, B. Haraoui Grant/research support from: AbbVie, Amgen, BMS, Janssen, Pfizer, Roche and UCB, Consultant for: AbbVie, Amgen, BMS, Celgene, Eli Lilly Janssen, Merck, Pfizer, Roche and UCB, Speakers bureau: Amgen,BMS Janssen, Pfizer and UCB, E. Keystone Grant/research support from: Abbott Laboratories, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, F.Hoffmann-La Roche Inc, Janssen Inc, Lilly Pharmaceuticals, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis, UCB, Consultant for: Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Crescendo Bioscience, F Hoffmann-La Roche Inc, Genentech Inc, Janssen Inc, Lilly Pharmaceuticals,Merck, Pfizer Pharmaceuticals, UCB, Speakers bureau: Abbott Laboratories, AstraZeneca LP, Bristol-Myers Squibb Canada, F Hoffmann-La Roche Inc, Janssen Inc, Pfizer Pharmaceuticals, UCB,Amgen, D. Tin: None declared, C. Thorne Grant/research support from: AbbVie, Amgen, Celgene, CareBiodam, Lilly, Norvartis, Pfizer, Sanofi, UCB, Consultant for: AbbVie, Amgen, Celgene, Centocor, Genzyme, Hospira Janssen, Lilly, Medexus/Medac, Merck, Novartis, Pfizer, Sanofi, UCB, Speakers bureau: Medexus/MEdac, J. Pope Grant/research support from: Amgen, BMS, Pfizer, Roche, UCB, Consultant for: AbbVie, Actelion, Amgen, Bayer, BMS, Genzyme, Hospira, Lilly, Merck, Norvartis, Pfizer, Regeneron, Roche, Sandofi, UCB, V. Bykerk Shareholder of: Biogen (family), Consultant for: Abbvie, Pfizer, Genenech/Roche, Regeneron, BMS, UCB, Employee of: Biogen (family), C. Hitchon Grant/research support from: UCB
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI